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ROLE OF NITRIC OXIDE IN SJOGREN’S SYNDROME 
YRJO T. KONTTINEN, LOUISE A. M. PLATTS, SUSANNE TUOMINEN, KARI K. EKLUND, 
NINA SANTAVIRTA, JYRKI TORNWALL, TIM0 SORSA, MIKA HUKKANEN, and JULIA M. POLAK 
Objective. To measure levels of salivary nitrite 
(NO2-) and to localize nitric oxide synthases (NOS) in 
the labial salivary glands (LSGs) of patients with Sjo- 
gren’s syndrome (SS). 
Methods. NO2- was measured by the Griess 
reaction. LSGs were analyzed using NADPH-diaphorase 
histochemical and immunohistochemical studies to de- 
termine the constitutive NOS (neuronal [neNOS] and 
endothelial [ecNOS]) and inducible NOS (INOS) 
isoforms. 
Results. The NO2- concentration (mean f SEM 
307 f 51 pillversus 97 f 16 E.cM; P c 0.05) and output 
(166 2 46 nmoles/minute versus 37 f 7 nmoles/minute) 
were increased in S S  patients compared with healthy 
control subjects. NADPH-diaphorase was found in some 
nerve fibers and endothelial cells, and, in SS, was found 
in myoepithelial, acinar, and ductal epithelial cells, but 
in only a few inflammatory cells. In SS, ncNOS- 
immunoreactive nerve fibers were sparse and ecNOS 
was found in a minority of the CD31-positive vascular 
endothelial cells and acinar cells, whereas iNOS was 
localized in myoepithelial, acinar, and ductal epithelial 
cells, often together with tumor necrosis factor a. 
Conclusion. Nitrite was found in normal human 
saliva. NO produced by ncNOS probably acts as a non- 
adrenergic, noncholinergic neurotransmitter, whereas 
that produced by ecNOS exerts a vasodilatory effect. S S  
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patients had increased NO,- concentrations, with most 
of the superfluous salivary NO being produced not by 
the immigrant inflammatory cells, but rather, by the 
resident salivary gland cells. NO may contribute to 
inflammatory damage and acinar cell atrophy in SS. 
Nitric oxide (NO) is produced by vascular endo- 
thelium, nerve terminals, and inflammatory cells in a 
reaction catalyzed by NO synthase (NOS), which con- 
verts L-arginine to NO and L-citrulline (1). NOS occurs 
in at least 3 different isoforms, endothelial constitutive 
NOS (ecNOS), neuronal constitutive NOS (ncNOS), 
and inducible NOS (iNOS) (2,3). Both ecNOS and 
ncNOS are constitutively expressed, but are regulated as 
to their level of activity by various soluble ligands and/or 
shear forces through calcium/calmodulin-dependent sec- 
ond messenger pathways. NO concentrations produced 
by this route are usually relatively low (in the picomolar 
range). In contrast, regulation of iNOS occurs at the 
level of gene transcription and is relatively slow, but 
leads to long-lasting and significant increases in NO 
production (giving rise to nanomolar local concentra- 
tions of NO) (1,3,4). 
NO has a short half-life and is rapidly converted 
to nitrites and nitrates. Therefore, its range of action is 
limited. This is important from the point of view of 
regulation, because NO itself is a small, lipid-soluble 
compound, which easily penetrates the cell membrane of 
nearby cells and can therefore affect them in a receptor- 
independent autocrine and/or paracrine manner. At the 
same time, NO is a highly reactive compound, due to an 
unpaired electron in its molecular orbital. At low con- 
centrations, it preferentially activates guanylate cyclase, 
which thus produces cGMP. At high concentrations, NO 
inhibits various iron-containing DNA synthetases and 
mitochondria1 enzymes, and thus inhibits cell growth 
and division, finally leading to cell death (5).  
Due to its potential dual role in normal salivary 
gland function and damage in pathologic conditions, it 
was considered important to characterize the eventual 
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presence of NO in saliva and to localize the cells/NOS 
isoforms responsible for NO production in patients with 
Sjogren’s syndrome (SS) .  
PATIENTS AND METHODS 
Patients and samples. All patients and healthy volun- 
teers gave their informed consent. The Declaration of Helsinki 
(6) was followed throughout the study, which was approved by 
the local ethics committee. 
Both patients and controls provided a stimulated sali- 
vary sample, as described elsewhere (7). Briefly, stimulation of 
saliva was achieved by the chewing of paraffin for 5 minutes, 
and the stimulated whole saliva was then collected. Immedi- 
ately after collecting the saliva, the samples for NO2- mea- 
surement were centrifuged at 1,OOOg for 5 minutes, and the 
supernatants were frozen at -70°C until analyzed. For vaso- 
active intestinal peptide (VIP) measurement, the saliva was 
collected into chilled tubes containing 50,000 IU/ml aprotinin 
and 10 mM EDTA to minimize artifactual neuropeptide 
degradation in vitro (8). 
The mean age of the 12 primary S S  patients, who were 
all women, was 51.6 years (range 21-74). The duration of the 
S S  was a mean of 9 years (range 1-23). All patients were 
nonsmokers. The mean age of the 10 healthy control women 
was 47.7 years (range 39-56). 
The dental/periodontal features of all patients were 
evaluated for decayed, missing, or filled surfaces using the 
DMFS index (9), bleeding on probing using the BOP index 
(lo), presence of visible plaque using the visible plaque index 
(1 l), retentive calculus (subgingival calculus) using the RC 
index (12), items on the community periodontal index of 
treatment needs (13), and pocket probing depth (10). Eventual 
correlations were sought between the dental and periodontal 
status and salivary NO,- concentration. 
Between 6 and 8 labial salivary glands (LSGs) were 
obtained from each patient by biopsy. Samples were taken by 
blunt dissection under infiltration anesthesia and fixed by 
immersion in freshly made 1% paraformaldehyde in 0.01M 
phosphate buffered 0.15M saline (PBS; pH 7.1) at 4°C for 
16-18 hours. After fixation, cryoprotection was performed in 
15% (weight/volume) sucrose and 0.01% (w/v) sodium azide in 
PBS for several days at 4°C before the samples were embedded 
in Tissue-Tek OCT compound (Lab-Tek Products, Elkhart, 
IN), snap frozen in liquid nitrogen, and stored at -70°C until 
staining. LSGs were obtained from 4 patients with S S  who 
fulfilled the European criteria for SS (14), and from 2 healthy 
controls who did not have S S  (14) and who had a focus score 
of <1 (15). 
Jenkins activity survey (JAS). The JAS scale consists 
of 84 items, which are divided into 4 subscales. For the present 
study, we recorded the values of the actual A-B factor, which 
involves 21 items on the JAS that best reflect the stress 
behavior of a person (16). The reliability of the stress factor 
was confirmed with the use of the Cronbach a test (17). 
Nitrite analysis. NO,-, a stable end-product of NO 
oxidation, was measured using the Griess reagent, consisting of 
equal volumes of 0.1% N-(1-naphthy1)ethylenediamine HCI 
and 1% sulfanilamide plus 5% H,PO, (18). Briefly, 5O-pI 
aliquots of the saliva sample, in duplicate, from each donor 
were incubated with an equal volume of the Griess reagent in 
a 96-well U-bottomed microtiter plate for 5 minutes at 22°C. 
With each study, a standard curve was established using 
NaNO, in a range of 10-1,000 for each assay. After a 
10-minute reaction, the microplate was read on a spectrophoto- 
meter at 545 nm. The data were derived from the slope of the 
standard curve and were presented as the mean value of the 
duplicates. Results of the salivary NO2- measurements were 
expressed as a concentration (in pM), but also as NO2- output 
(output = concentration x volume; in nmoles/minute). 
NADPH-diaphorase histochemical analysis. For histo- 
chemical demonstration of NADPH-diaphorase activity, which 
is an indicator of NOS activity, freshly cut and PBS-rinsed 
10-pm cryostat sections from the midsagittal plane of LSGs 
were mounted on formol-gelatin-coated slides and incubated 
in 1 mM p-NADPH, 0.5 mM nitroblue tetrazolium, 1.5 mM 
L-malic acid, and 0.1% Triton X-100 in 50 mM Tris HCl, pH 
7.4, at 37°C for 1 hour. Finally, slides were rinsed in distilled 
water and mounted (19). This procedure resulted in an intense 
deep-blue nitroblue tetrazolium formazan formation, which 
was not observed when NADPH was not added to the reaction 
mixture. 
Acetylcholinesterase histochemical analysis. Acetyl- 
cholinesterase activity in LSG tissue was visualized as previ- 
ously described (20). Briefly, the cryostat sections were first 
immersed in an incubation medium for 45 minutes at 37°C. 
The acetylcholinesterase activity was then visualized by immer- 
sion of the sections for 5 minutes in 50 mMTris HCl buffer, pH 
7.6, containing 0.04% 3,3’-diaminobenzidine and 0.3% nickel 
ammonium sulfate. Sections were incubated in this solution for 
a further 5 minutes after addition of hydrogen peroxide, for a 
final concentration of 0.003%. 
Immunocytochemical analysis for NOS. Polyclonal 
antibodies for the cNOS and iNOS isoforms used in this study 
have been characterized in detail elsewhere. Briefly, antibodies 
for ncNOS, kindly provided by Drs. S .  Moncada and V. 
Riveros-Moreno (Wellcome Research Laboratories, Becken- 
ham, Kent, UK), were raised against the whole protein puri- 
fied from rat brain and against synthetic peptide fragment 53 
of rat brain ncNOS; both of these antisera cross-react with the 
ecNOS isoform at high concentrations (21). Monoclonal anti- 
bodies for ecNOS were raised against a purified whole protein 
of particulate bovine aortic endothelial NOS isoform (22) and 
were kindly provided by Dr. J. S .  Pollock (Abbott Laboratories, 
Abbott Park, IL). Antibodies for iNOS were raised against 
synthetic peptides corresponding to amino acid residues 47-71 
of murine macrophage iNOS and 54-76 of human hepatocyte 
iNOS (23-25). Murine macrophage iNOS antibodies were 
kindly provided by Drs. S .  Moncada and V. Riveros-Moreno 
(Wellcome Research Laboratories) and human hepatocyte 
iNOS antibodies by Dr. T. J. Evans (Royal Postgraduate 
Medical School). 
Antibodies against the synthetic 47-71 peptide of 
macrophage iNOS have been characterized for specificity in 
detail elsewhere, with the use of an antigen preabsorption test 
and Western blotting (25). Similarly, the specificity of the 
human hepatocyte iNOS antibodies have been confirmed by 
antigen reabsorption test with the use of a synthetic 54-76 
peptide, by Western blotting, and by comparison with in situ 
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hybridization (26). There was no cross-reactivity between 
ecNOS and iNOS antibodies. 
Antibodies against tumor necrosis factor a (TNFa; Dr. 
W. A. Buurman, University of Limburg, Maastricht, The 
Netherlands) and CD68 (Dako, Glostrup, Denmark) were 
used to demonstrate a possible induction mechanism of iNOS 
and its localization in macrophages. Antibodies against CD31 
(platelet endothelial cell adhesion molecule; Dr. A. V. Ma- 
zurov, Institute of Experimental Cardiology, Cardiology Re- 
search Centre, Moscow, Russia) and against nitrotyrosine 
(TCS Biological, Bucks, UK) were used, in some cases, to 
demonstrate endothelial cells and the possible site of action of 
oxidative NO-induced damage in inflammatory LSG tissue, 
respectively. 
Fifteen micrometer-thick cryostat sections were cut 
through the midsagittal planes of LSGs, transferred onto 
formol-gelatin-coated slides, and allowed to dry for 1 hour 
before any further procedures were carried out. Endogenous 
peroxidase was inhibited by soaking the sections in 0.3% (v/v) 
hydrogen peroxide in methanol at 4°C for 20 minutes. The 
sequential sections were then placed in a humid chamber and 
incubated 1) overnight at 4°C with primary antibodies as 
described above; 2) for 30 minutes at 22°C with biotinylated 
goat anti-rabbit (for polyclonal antibodies) or horse anti- 
mouse (for monoclonal antibodies) IgG (Vector Laboratories, 
Peterborough, UK), diluted 1:lOO in PBS with 0.1% w/v bovine 
serum albumin; and 3) for 60 minutes at 22°C with avidin- 
biotin-peroxidase complex (ABC; avidin and biotinylated 
horseradish peroxidase diluted 1:200 in 0.1M PBS, pH 7.4 [27], 
for 5 minutes at 22°C with 3,3'-diaminobenzidine and nickel 
ammonium sulfate containing glucose and glucose oxidase). 
After each step, the slides were rinsed 3 times in PBS for 5 
minutes. Finally, the slides were dehydrated in ethanol, cleared 
in Inhibisol (Kalon Chemicals, Cramlington, UK), and 
mounted in Pertex (Histolab Products, Gothenburg, Sweden). 
Omission of the primary antibodies and use of irrele- 
vant immunoglobulin from the same species and of the same 
class, isotype, and concentration were used as staining con- 
trols. Conventional hematoxylin and eosin staining of sequen- 
tial sections was used for comparative histopathologic analysis. 
Other immunohistochemical analyses. VIP immuno- 
localization was performed using specific antibodies and the 
ABC technique, as described in detail elsewhere (28,29). All 
samples were also stained with anti-CD31, anti-CD68, and 
antimyeloperoxidase antibodies as markers for endothelial 
cells, macrophages, and neutrophils, respectively. Further- 
more, all samples were similarly assessed for the presence, 
localization, and extent of expression of TNFa. 
An indirect immunofluorescence method was used for 
colocalization of iNOS and CD68-positive macrophages. Cry- 
ostat sections, 7-10-pm thick, mounted on formol-gelatin- 
coated slides, were washed in PBS and incubated with 1) 
diluted normal goat serum for 30 minutes at 22°C before 
blotting it away; 2) monoclonal anti-CD68 antibodies for 16 
hours at 4°C; 3) tetramethylrhodamine isothiocyanate 
(TR1TC)-labeled goat anti-mouse IgG antiserum (1: 100) for 
60 minutes at 22°C in the dark; 4) polyclonal iNOS antibodies 
(1:300) for 16 hours at 4°C in the dark; and 5) fluorescein 
isothiocyanate (F1TC)-labeled goat anti-rabbit IgG (1:lOO) for 
60 minutes at 22°C in the dark before mounting with Vecta- 
shield (Vector Laboratories) to reduce quenching of the 
Table 1. Correlations between the salivary nitrite (NO,-) concen- 
tration and dental and periodontal status of 10 patients with Sjogren's 
syndrome* 
Spearman's rank correlation 





PPD (4-5 mm) 







* DMFS = decayed, missing, or filled surfaces; BOP = bleeding on 
probing; VPI = visible plaque index (yedno); RC = retentive calculus 
(subgingival calculus); PPD = pocket probing depth. The community 
periodontal index of treatment need values were zero for all patients 
studied. None of the correlations were statistically significant. 
fluorescent signal. Between the steps, slides were washed in 
PBS, if not stated otherwise. Immunostained preparations 
were examined using an Olympus BX60 (Olympus Optical, 
Tokyo, Japan) research microscope with selective filters for 
specific emission wavelengths of TRITC and FITC. 
Cell counting. The total number of CD68-positive 
macrophages and cells immunoreactive for the murine and 
human iNOS antibodies were counted manually using a grati- 
cule and a 20X objective magnification. Four randomly se- 
lected fields which contained at least 1 inflammatory cell focus 
with more than 50 inflammatory mononuclear cells were 
counted in each study subject. The cells that were counted 
included inflammatory cells, acinar cells, and some ductal 
epithelial cells. Cells with typical mast cell morphology were 
excluded from cell counts. 
Radioimmunoassay for VIP. The neuropeptide con- 
centration in saliva was measured using a standard competitive 
'251-radioimmunoassay kit (Peninsula, Belmont, CA) as de- 
scribed in detail elsewhere (8). Briefly, 1) 100 p1 of sample or 
standard was incubated in polypropylene tubes for 24 hours at 
4°C with 100 pl of rabbit anti-human VIP IgG, 2) 100 p1 of 
1251-labeled peptide (10,000-15,000 counts per minute/100 pl) 
was added and incubated for 24 hours at 4"C, 3) 100 pl of goat 
anti-rabbit IgG and 100 pl of normal rabbit serum were added 
and incubated for 90 minutes at room temperature before 4) 
500 pl of radioimmunoassay buffer was added, followed by 
centrifugation at 1,700g for 20 minutes at 4°C. The supernatant 
was discarded and the radioactivity of the pellet was measured 
with a programmed gamma scintillation counter. All samples 
were analyzed in duplicate, with individual controls for appar- 
ent binding in the absence of antibody (i.e., total counts, 
nonspecific binding, total binding). 
Statistical analysis. Results are presented as the 
mean ? SEM. Comparisons between the 2 groups were 
performed with the Student's t-test for normally distributed 
variables, and with the Mann-Whitney U test for non-normally 
distributed variables. For analysis of the linear relationship 
between 2 variables, Pearson's correlation coefficient was used 
for normally distributed variables and Spearman's rank corre- 
lation coefficient for non-normally distributed variables. 
BMDP-PC, version 7.01 (BMDP Statistical Software, Cork, 
Ireland), statistical software was used for all calculations 
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Figure 1. Histochemical and immunohistochemical localization of NADPH-diaphorase activity and the 3 different isoforms of nitric oxide synthase 
(NOS) in labial salivary glands from patients with Sjogren’s syndrome. A, Histochemical demonstration of NADPH-diaphorase activity within 
myoepithelial cells (arrows) and acinar cells of acini (open arrow) and excretory duct epithelia (arrowheads). B, Neuronal NOS immunoreactivity 
in nerve fibers (arrows) terminating near an acinus. Neuronal NOS-containing nerve fibers can also been seen in connective tissue surrounding the 
acinus. C, CD31-positive vascular endothelial cells (arrows) within a small focal inflammatory cell infiltrate surrounding an excretory duct. D, 
Endothelial NOS (arrows) was found to colocalize with CD31-positive cells, as evidenced by immunostaining of serial sections. E, Immunoreactivity 
for endothelial NOS in several acini localized mainly in acinar cells (arrows). F, Antibodies for human hepatocyte inducible NOS (iNOS) isoform 
reveal numerous iNOS-immunoreactive mononuclear cells (open arrows) within an inflammatory cell infiltrate. (Original magnification X 400.) 
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except for those in the JAS, which were analyzed using the 
SPSS software package (SPSS Inc., Chicago, IL). 
RESULTS 
Relationship of salivary NO,- to SS, stress, and 
VIP. The NO,- concentration was higher in patients 
with SS (mean 2 SEM 307 2 51 CLM) than in healthy 
control individuals (97 ? 16 pA4; P < 0.05). There was 
no correlation between the salivary NO2- concentration 
and the dental or periodontal status of the SS patients 
(Table 1). The NO2- output was 37.2 f- 6.6 nmoles/ 
minute in healthy controls compared with 166.3 i 46.2 
nmoles/minute in patients with SS (P < 0.01). The 
salivary VIP concentration was 68.6 i 24.2 pg/ml in the 
patient group compared with 40.8 t 23.6 pg/ml in the 
healthy control group (P < 0.05). However, there were 
no significant correlations between salivary NO2- and 
VIP concentrations or between salivary NO2- concen- 
tration and stress in the patients or in the controls. 
NADPH-diaphorase activity in LSGs in SS. The 
most conspicuous finding was that, in the LSGs, intense 
NADPH-diaphorase activity was localized in myoepithe- 
lial cells of the glandular acini and less frequently in 
acinar end-piece cells (Figure 1A). Epithelial cells of 
intercalated, striated, and excretory ducts also showed 
intense NADPH-diaphorase activity (Figure 1A). It 
was particularly interesting that such epithelial-cell 
NADPH-diaphorase expression was also seen in 
the LSGs obtained from healthy controls. NADPH- 
diaphorase activity was found in some nerve trunks, 
fibers, and terminals located around the acini and sali- 
vary ducts. Such NADPH-diaphorase-containing nerve 
fibers and terminals were relatively evenly distributed, 
but seemed to be absent from lymphocyte-infiltrated 
areas (i.e., lymphocyte foci) in SS patients. 
NADPH-diaphorase activity was less frequently 
localized in endothelial cells of arterioles, capillaries, or 
venules. NADPH-diaphorase-positive endothelial cells 
were, in particular, observed in lymphocyte infiltrates in 
SS patients (for more details, see below). NADPH- 
diaphorase activity was seen in only a few of the inflam- 
matory cells of the characteristic focal lymphocyte-rich foci 
(for more details, see below). 
Neuronal cNOS in LSGs in SS. Antibodies raised 
against the whole ncNOS protein purified from rat brain 
and the synthetic peptide fragment 53 of rat brain 
ncNOS showed a very sparse distribution of ncNOS- 
containing nerve fibers, mainly localized around the 
acini and along the salivary ducts (Figure 1B). However, 
ncNOS immunoreactive nerve fibers were not seen in 
inflammatory cell foci in SS. In contrast, acetylcholines- 
terase histochemical and immunocytochemical localiza- 
tion of VIP-containing nerve fibers revealed a very 
dense distribution of cholinergic and VIPergic (para- 
sympathetic) nerve fibers coiling around the acini and 
salivary ducts in noninflammed areas of LSG, although 
such fibers appeared to be mostly absent from the 
lymphocyte foci in SS (data not shown). 
Endothelial cNOS in LSGs in SS. Monoclonal 
antibodies raised against the bovine aortic ecNOS iso- 
form revealed a very sparse endothelial cell ecNOS 
immunoreactivity compared with immunoreactivity for 
CD31. However, it was of interest to note that in SS, 
CD31-positive endothelial cells in focal inflammatory 
cell infiltrates showed a strong immunoreactivity for 
ecNOS (Figures 1C and D). Some ductal epithelial cells 
showed dense granular immunoreactivity and many 
acini were also immunoreactive for this antiserum 
(Figure 1E). 
Inducible NOS in LSGs in SS. Antibodies raised 
against both the murine macrophage and human hepa- 
tocyte iNOS peptide sequences were used in the present 
study. The 2 antibodies gave somewhat different profiles 
of iNOS-immunoreactive cells in inflammatory LSG 
tissue. Murine macrophage iNOS antiserum showed 
immunoreactivity for acinar structures and some inflam- 
matory cells, whereas human hepatocyte iNOS antibod- 
ies showed more frequent immunoreactivity for mono- 
nuclear inflammatory cells (Figure 1F) as well as for 
some ductal epithelial cells (data not shown). 
In SS patients, granular TNFa staining was seen 
in some acini, vascular endothelial cells, and, most 
notably, ductal epithelial cells. Immunostaining of serial 
sections for TNFa and human hepatocyte iNOS peptide 
sequence showed colocalization of TNFa with iNOS in 
ductal epithelial cells, but not in acinar or vascular 
endothelial cells (Figures 2A and B). 
The chemical reaction of NO with superoxide 
generates peroxynitrate, which has been shown to cause 
nitration of protein tyrosine groups. Antibodies against 
nitrosylated tyrosine (nitrotyrosine) residues labeled 
some ductal epithelial cells, but mainly detected nitro- 
tyrosine in periductal connective tissue. Periacinar con- 
nective tissue was also, in some cases, nitrotyrosine 
positive, but nitrotyrosine immunoreactivity could not 
be detected within the acinar cells (data not shown). 
Nitrotyrosine-staining controls were negative. 
Cell counting showed human hepatocyte iNOS in 
some immigrant inflammatory cells in the lymphocyte- 
rich foci in patients with SS. Approximately 16 ? 3 
(mean 2 SEM) such cells were seen per 1 mm2 of 
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Figure 2. Immunoreactivity for human inducible nitric oxide synthase (iNOS) antibodies (A) (arrows) was found to colocalize with that for tumor 
necrosis factor a (TNFa) (B) (arrows) in ductal epithelial cells in labial salivary glands from patients with Sjogren’s syndrome. The 2 sections 
immunostained for iNOS and TNFa were taken 40 pm apart, but several ducts can still be traced through the tissues. Note the absence of iNOS 
and TNFa immunoreactivity in acini. (Original magnification X 400.) 
inflammatory cells, compared with 21 2 2 CD68+ 
macrophages. However, colocalization studies with dou- 
ble labeling suggested that there was only a minor 
overlap between these 2 cell subpopulations (data not 
shown), although some CD68-positive macrophages 
were also immunoreactive for human hepatocyte iNOS 
(Figures 3A and B). 
DISCUSSION 
SS is characterized by a focal adenitis, autoimmu- 
nity, and sicca symptoms. In salivary glands, this is 
expressed in the form of focal T lymphocyte-rich infil- 
trates and xerostomia. The simplistic and prevailing view 
has been that sialopenia and xerostomia are due to 
structural destruction of the secretory acinar cells, which 
are responsible for the secretion of the primary saliva. 
However, there is a clear discrepancy between the often 
focal and local salivary gland involvement and the 
greatly diminished salivary flow seen in SS. Significantly, 
many patients draw advantage from the use of sialo- 
gogues, such as xylitol gum or pilocarpine. Therefore, an 
alternative hypothesis has been that, before permanent 
Figure 3. Indirect immunofluorescence technique was used for colocalization of inducible nitric oxide synthase (INOS) immunoreactivity (A) 
(arrows) with CD68-positive macrophages (B) (arrows). In these photomicrographs, only 2 CD68-positive macrophages (B) also express iNOS 
immunoreactivity, although some additional inflammatory and/or resident cells were immunoreactive for the iNOS isoform (A). (Original 
magnification X 450.) 
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salivary gland parenchymal damage has occurred in a 
long-lasting and chronic disease, the focal perivascular 
and periductal inflammation alters the vasoneural regu- 
lation of the various vascular, motor, and secretory 
components of the normal salivary flow. 
Using VIP and neuropeptide Y as markers for 
postganglionic parasympathetic and sympathetic nerve 
fibers, respectively, a clearly decreased innervation of 
the salivary glands in SS has been shown (28,29). In 
addition to adrenergic and cholinergic nerves, the non- 
adrenergic, noncholinergic system plays a role in normal 
and abnormal neuronal regulation of the salivary glands. 
An important part of the nonadrenergic, noncholinergic 
system is mediated by VIP, which, via its low-affinity 
binding sites, is linked to CAMP formation and, via its 
high-affinity binding sites, to Ca2+ mobilization and 
promotion of neuronal survival (30-32). More recently, 
NO has been measured in human saliva (33). It was also 
confirmed that NO is released from salivary glands 
rather than being produced from the activity of oral 
bacteria (33). Furthermore, there were no significant 
correlations between the salivary NOz- concentration 
and the periodontal status of the SS patients, which rules 
out any contribution of inflammatory gingival crevicular 
fluid to the salivary NO2-. This is consistent with recent 
studies on the presence of NADPH-diaphorase activity 
and NOS isoforms in feline submandibular glands (34) 
and with the current findings on the presence of 
NADPH-diaphorase activity and of all 3 different NOS 
isotypes in human salivary glands. 
Formation of primary saliva involves vasodilation 
and acinar cell secretion. Changes in the regulatory 
vasoneural interactions may lead to sialopenia and dry 
mouth, such as is seen in psychogenic dry mouth in 
depression and anxiety or as an anticholinergic side 
effect of many widely used drugs. Changes in the 
L-arginine/NO-generating pathway may contribute to 
these crucial events. NO may influence parasympathetic 
vasodilation and salivary flow by regulating peptide 
release and second messenger systems for both VIP and 
acetylcholine, as has been shown in pigs and rats (35- 
37). As described in the present study, the elements of 
the L-arginine/NO-generating pathways are also found in 
human salivary glands and saliva. 
There were some interesting differences between 
the SS patients and controls. The increase in NO,- seen 
in SS may have been related to an inflammation-induced 
increase in the expression of the iNOS rather than to the 
increased activity of the cNOS isoforms. The increased 
salivary NOz- concentration is not likely to be a reflec- 
tion of the decreased “water” content of the saliva, 
because the salivary NO2- output was also significantly 
higher in the SS patients than in the controls. Further- 
more, a decrease in the salivary gland tissue mass, e.g., 
by replacement with inflammatory cell infiltrates, fibro- 
sis, and fat atrophy, would lead to an apparently low 
salivary NO2- concentration, so that a 50% decrease in 
the mass would decrease the salivary NO2- 
concentration/output by half. Perhaps even more impor- 
tantly, deranged architecture/function of the diseased 
glandular tissue would also contribute to an apparently 
low salivary NO,- concentration/output, so that a 50% 
decrease in the function would also decrease the salivary 
NO,- concentration/output by half. Therefore, the ob- 
served differences between patients and controls may 
reflect quite significant differences in the salivary gland 
tissues. 
Studies in pigs have demonstrated that release of 
VIP from the salivary gland, elicited by parasympathetic 
stimulation (10 Hz, 30 seconds), was markedly reduced 
by a NOS inhibitor, p-nitro-L-arginine (36,37). Inter- 
estingly, in the present study, no significant correlations 
were found between the salivary NO,- and VIP concen- 
trations, suggesting that this NO-mediated regulation of 
VIP release may not be the only system controlling VIP 
release from the peripheral VIPergic nerve fibers in 
human salivary glands. 
In addition to the constitutively expressed and 
rapidly regulated endothelial and neuronal NOS, iNOS 
has been described in numerous cell types. However, the 
presence of iNOS in human macrophages is still a matter 
of controversy (38,39). The iNOS gene is located in 
chromosome 7, and its level of expression is regulated by 
various cytokines and lipopolysaccharides. In particular, 
certain cytokine combinations, such as interferon- y 
(IFNy), interleukin-1 (IL-l), and TNFa, are very effec- 
tive and synergistic in the up-regulation of iNOS gene 
expression (40,41). Inducible NOS produces high con- 
centrations of NO for extended time periods, and, often, 
high cytotoxic and bactericidal concentrations of NO are 
produced. 
Increased NO production hardly represents at- 
tempts to compensate for diminished cholinergic stimu- 
lation. It seems that the increased NO production is 
caused by local inflammatory changes and by cytokines, 
and, as such, appears to be an effect of inflammation 
rather than of a physiologic process intended to com- 
pensate for diminished cholinergic Stimulation. More- 
over, increased inflammatory NO production mediated 
by iNOS might not be able to compensate for the highly 
regulated neuronal events that are involved in the 
coordinated vascular, motor, and secretory components 
of the reflex salivary flow. Inflammatory NO production 
would be very unlikely to have that type of effect, 
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coordinated in time and at site, that is characteristic of a 
well-functioning normal neurovascular system of the 
salivary gland. 
It was of particular interest to note that NADPH- 
diaphorase activity and, to a lesser extent, iNOS expres- 
sion, were seen in the acinar and ductal epithelial cells of 
LSGs from SS patients, but also to some extent in those 
from healthy controls. In thyroid glands, NADPH- 
diaphorase activity and NOS immunoreactivity have 
been described in nerve fibers and vascular endothelium, 
but not in the glandular parenchymal cells (42). Lohinai 
and coworkers, in a study of feline submandibular glands, 
noticed that the epithelial layer of the salivary ductal 
branches was NOS immunonegative, but NADPH- 
diaphorase positive (34). Inducible NOS/NADPH- 
diaphorase in salivary glands might be induced by bac- 
terial lipopolysaccharides (40). However, considering 
the cytokine-mediated regulation of iNOS, it seems 
more likely that in SS, iNOS immunoreactivity and 
NADPH-diaphorase activity are induced by cytokines, 
such as TNFa, IL-1, and IFNy (40,41), which are 
produced by the salivary gland epithelial cells and/or 
activated T lymphocytes (43-45). 
One interesting feature of the minor salivary 
glands is the occurrence of focal accumulations of 
lymphocytes around the duct walls (46-48), which are 
believed to have a role in the immune surveillance of the 
mouth (48). Although the control LSGs were from 
subjects who did not have SS and who had a focus score 
(10) of 4 ,  they did have occasional lymphocyte foci. 
These foci might produce enough cytokines (43-45) to 
up-regulate the iNOS immunoreactivity/NADPH- 
diaphorase activity even in normal minor salivary glands, 
although not to the same extent as in SS, as suggested by 
the present findings on salivary NOz- concentration. 
The salivary concentration of NO2- may not 
quite reflect the extent of local NO production, because 
at least part of the locally produced NO could be 
disposed via pathways other than that leading to saliva. 
It is therefore possible that the increased, inflammation- 
associated, and probably cytokine-induced local NO 
production in SS interferes with the normal function of 
the cNOS isoforms and may, by itself, lead to cytopathic 
changes and acinar cell atrophy. 
Thus, NO is produced in physiologic amounts in 
normal salivary glands mainly by constitutively expressed 
ncNOS and ecNOS isoforms, and may contribute to 
various events that regulate vascular reactivity, salivary 
flow, and neuropeptide release. In focal adenitis in SS, 
cytokine-induced iNOS is expressed by salivary gland 
acinar and ductal epithelial cells together with TNFa, 
suggesting a role for these resident cells in local patho- 
mechanisms, which may contribute to various cytopathic 
and atrophic cell changes. 
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